ENW News
"ENW looking interesting, little worried about investing in an area I know nothing about. Stocks at 52 weeks high. I will track it to see how it trades.
"
As I said earlier, I'm not sure that this will be a trading stock but the potential of what they are developing seems incredible.
The same institutional broker that brought Sensio around to its clients and launched it is getting behind Enwave. Full disclosure, I've built up a large position and will be holding for multiple dollars.
TSX Venture Exchange trading symbol: ENW
www.enwave.net
EnWave Announces Successful Test Results
for Antibodies Using freezeREV Dehydration Technology
Vancouver, B.C., September 24, 2009
EnWave Corporation (TSX-V: ENW) (“EnWave” or “the Company") today announced that it has successfully dried three different antibodies in the Company’s prototype freezeREV vial dehydration technology. Results from this study showed no detectable visual difference between freezeREV-dried and
freeze dried samples when examined with the SDS-PAGE electrophoresis method. Additionally, the indication of the molecular weight was similar between the two dried samples and liquid antibodies.
The current industry process of freeze drying, or lyophilization, can be particularly harsh on sensitive
materials such as antibodies because of the length of time that organisms are exposed to extremely low
temperatures. The freezeREV prototype has been designed to significantly reduce the drying time and
temperature exposure from days, to minutes or hours, creating the potential for a high-speed, cost
effective dehydration technology. The Company believes that a commercial-scale freezeREV machine
could reduce the costs of dehydration for live or active pharmaceuticals and reagents by as much as
80%.
“These are exciting results for the company as we are seeing the potential of this technology in a new
area of biopharmaceuticals and biomaterials” said Dr. Durance. “We have tested a variety of proteins in
the past, but antibody dehydration could open up a huge new market for EnWave, and this would
compliment our existing research into vaccine dehydration.”
The three polyclonal antibodies used in this study were derived from chicken, rabbit and bovine blood
serum, and are used by the pharmaceutical industry for drug research. They are also used in the
production of animal vaccines, and as feed additives to improve animal health. Dehydration of antibodies
is important to the pharmaceutical and biotechnology sectors, primarily because the process increases
the shelf-life of these expensive and difficult-to-manufacture organisms. Antibodies are infection fighting
proteins used in a wide variety of applications including medical research and diagnostics, prenatal
therapy, and treatment of diseases such as cancer, heart disease, rheumatoid arthritis and multiple
sclerosis.
freezeREV is a dehydration method for biomaterials in vials where low moisture levels in the final product are imperative for long product shelf-life. This technology is being designed to create room temperature stable pharmaceuticals or reagents containing live organisms such as viruses, bacteria and antibodies where an emphasis must be placed on maintaining the maximum possible survival rates of these organisms until they are delivered to a patient.
EnWave has initiated a search for a major industry partner with whom to expand testing for both polyclonal and monoclonal antibody products with the goal of proving that freezeREV dehydration technology can be developed into a commercially viable method.
About EnWave
Using proprietary technologies developed in conjunction with the University of British Columbia, EnWave
is focused on the development of new methods of dehydrating food and biological materials using
Radiant Energy Vacuum technology under its nutraREVTM, powderREV, bioREVTM and freezeREV
brands. REV technology combines microwave energy transfer under vacuum to dehydrate and alter
structures and drive chemical reactions, thereby creating unique product characteristics for both food
products and medical applications that include fruit, vegetables, probiotics, enzymes, proteins, food
cultures, vaccines and antibodies. More information about EnWave is available at www.enwave.net.
EnWave Corporation
Dr. Tim Durance
Chairman & Co-CEO
-end-
For further information:
Mr. John McNicol
President & Co-CEO
(604) 601-8524
john.mcnicol@enwave.net
Jennifer Thompson,
V.P. Corporate Development & Investor Relations
(604) 603-6549
jthompson@enwave.net
This press release may contain forward-looking information based on management's expectations,
estimates and projections. All statements that address expectations or projections about the future,
including statements about the Company's strategy for growth, product development, market position,
expected expenditures and financial results are forward-looking statements. These statements are not a
guarantee of future performance and involve a number of risks, uncertainties and assumptions: there is
no guarantee that the Company’s REV technology can or will improve dehydration processes in the target
industries; even if the Company’s REV technology can be used as described in this document, there is no
guarantee that such use will result in orders for the Company’s REV technology.
The TSX Venture Exchange has neither approved nor disapproved the information contained herein.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this
release. |
